BNP Paribas Exane analyst Navann Ty raised the firm’s price target on Phibro Animal Health (PAHC) to $37 from $24 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Corp’s Earnings Call Highlights Robust Growth
- Phibro Animal Health Faces AI-Driven Risks Threatening Business Stability
- Phibro Animal Health price target raised to $27 from $19 at BofA
- Phibro Animal Health Reports Strong Fiscal Year Results
- Phibro Animal Health: Strong Q4 Results and Strategic Growth Initiatives Tempered by Valuation Concerns Leading to Hold Rating